Compare HUBG & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBG | RXRX |
|---|---|---|
| Founded | 1971 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 1996 | 2021 |
| Metric | HUBG | RXRX |
|---|---|---|
| Price | $43.72 | $4.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $41.75 | $7.25 |
| AVG Volume (30 Days) | 777.9K | ★ 20.5M |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $3,728,870,000.00 | $43,689,000.00 |
| Revenue This Year | N/A | $7.79 |
| Revenue Next Year | $3.55 | $27.32 |
| P/E Ratio | $24.95 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.75 | $3.79 |
| 52 Week High | $49.60 | $12.36 |
| Indicator | HUBG | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.51 | 40.52 |
| Support Level | $42.37 | $4.61 |
| Resistance Level | $43.95 | $5.09 |
| Average True Range (ATR) | 1.22 | 0.26 |
| MACD | 0.34 | -0.00 |
| Stochastic Oscillator | 88.70 | 6.84 |
Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.